Streetbeat News

Regulatory

IMRX

Immuneering has been granted FDA Orphan Drug Designation for its drug IMM-1-104, aimed at treating pancreatic cancer. This designation can provide benefits such as tax credits, user fee waivers, and market exclusivity, potentially boosting the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:11 pm

BABA

JD

LI

NIO

US-listed Chinese stocks, including Alibaba, Nio, JD.Com, and Li Auto, saw significant declines as investors await clarity on China's fiscal stimulus plan. Concerns over the effectiveness of China's economic measures have led to skepticism in the market.

Portfolio Pulse from Pooja Rajkumari

October 15, 2024 | 12:11 pm

ALZN

Alzamend Neuro, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:09 pm

ANVS

Annovis Bio has received FDA clearance to begin pivotal Phase 3 studies for its Alzheimer's drug, Buntanetap, following positive Phase 2/3 data. This aligns the development path for New Drug Applications (NDAs) for Buntanetap.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:07 pm

WOLF

Wolfspeed shares rose following the announcement of a non-binding preliminary memorandum for up to $750 million in funding under the CHIPS and Science Act.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:05 pm

AMGN

Amgen presented Phase 3 MINT trial data for Uplizna, showing significant efficacy in treating generalized myasthenia gravis in AChR+ and MuSK+ patients. The trial also demonstrated corticosteroid tapering and no new safety signals.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:03 pm

BCTX

BriaCell is progressing with its Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The trial is active at 35 sites, with the primary endpoint being overall survival. Interim data analysis is planned at 144 events, potentially leading to full approval and marketing authorization. Patient enrollment is expected to complete by mid-2025, and no serious adverse events have been reported.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:56 am

LUCD

PAVM

Lucid Diagnostics has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method using methylation of the Cyclin-A1 gene to detect esophageal precancer and cancer.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:55 am

BTAI

BioXcel Therapeutics announced that the Department of Defense has granted funds to the University of North Carolina to study BXCL501. The Phase 2a trial for efficacy and safety is expected to begin enrollment in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:51 am

BTCUSD

Mark Cuban praised Vice President Kamala Harris for her evolving understanding of cryptocurrency, particularly Bitcoin, and her efforts to protect digital asset holders. Cuban highlighted Harris's recognition of the app economy and her proposal for a new regulatory framework supporting digital assets.

Portfolio Pulse from Khyathi Dalal

October 15, 2024 | 11:49 am